Condition: Breast Cancer · Sponsor: Hoffmann-La Roche
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
This description comes directly from the study's public registry record.
Reference Study ID Number: CO46274 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Avera Cancer Institute - Marshall | Marshall, Minnesota, United States | Recruiting |
| Avera Cancer Institute - Aberdeen | Aberdeen, South Dakota, United States | Recruiting |
| Avera Cancer Institute - Mitchell | Mitchell, South Dakota, United States | Recruiting |
| Avera Cancer Institute - Pierre, SD | Pierre, South Dakota, United States | Recruiting |
| Avera Cancer Institute | Sioux Falls, South Dakota, United States | Recruiting |
| AMG Oncology and Hematology Avera Cancer Institute - Yankton | Yankton, South Dakota, United States | Recruiting |
| Inst. Alexander Fleming | Buenos Aires, Argentina | Recruiting |
| Centro Oncologico Korben | Caba, Argentina | Recruiting |
| Centro Médico Fleischer | Capital Federal, Argentina | Recruiting |
| Sanatorio de la Mujer | Rosario, Argentina | Recruiting |
| Hospital Santa Rita de Cassia Vitoria | Vitória, Espírito Santo, Brazil | Recruiting |
| Hospital Brasilia | Brasília, Federal District, Brazil | Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07405801